Cancer epigenetics for the 21st century: What's next?

Genes and Cancer

Volumn 2, Issue 6, 2011, Pages 604-606

  Esteller, Manel ^a,b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

cancer; DNA methylation; epigenetics; histone; microRNA

Indexed keywords

MICRORNA;

ARTICLE; CANCER GENETICS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DNA MODIFICATION; EPIGENETICS; GENOME ANALYSIS; HISTONE MODIFICATION; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS;

EID: 80054779141     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911423096     Document Type: Article

References (37)

1. Fraga MF,Ballestar E,Paz MF, et al.Epigenetic differences arise during the lifetime of monozygotic twins.Proc Natl Acad Sci USA. 2005;102:10604-9.
2. Jones PA,Baylin SB.The epigenomics of cancer.Cell. 2007;128:683-92.
3. Feinberg AP.Phenotypic plasticity and the epigenetics of human disease.Nature. 2007;447:433-40.
4. Rodríguez-Paredes M,Esteller M.Cancer epigenetics reaches mainstream oncology.Nat Med. 2011;17:330-9.
5. Esteller M,Garcia-Foncillas J,Andion E, et al.Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.N Engl J Med. 2000;343:1350-4.
6. Esteller M,Sanchez-Cespedes M,Rosell R,Sidransky D,Baylin SB,Herman JG.Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.Cancer Res. 1999;59:67-70.
7. Maunakea AK,Nagarajan RP,Bilenky M, et al.Conserved role of intragenic DNA methylation in regulating alternative promoters.Nature. 2010;466:253-7.
8. Hansen KD,Timp W,Bravo HC, et al.Increased methylation variation in epigenetic domains across cancer types.Nat Genet. 2011;43:768-75.
9. Saito Y,Liang G,Egger G, et al.Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.Cancer Cell. 2006;9:435-43.
10. Lujambio A,Ropero S,Ballestar E, et al.Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.Cancer Res. 2007;67:1424-9.
11. Lujambio A,Portela A,Liz J, et al.CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer.Oncogene. 2010;29:6390-401.
12. Melo SA,Ropero S,Moutinho C, et al.A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function.Nat Genet. 2009;41:365-70.
13. Hill DA,Ivanovich J,Priest JR, et al.DICER1 mutations in familial pleuropulmonary blastoma.Science. 2009;325:965.
14. Melo SA,Moutinho C,Ropero S, et al.A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells.Cancer Cell. 2010;18:303-15.
15. Fernandez AF,Assenov Y,Martin-Subero JI, et al.A DNA methylation fingerprint of 1628 human samples.Genome Res. 2011;:.
16. Sandoval J,Heyn HA,Moran S, et al.Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome.Epigenetics. 2011;6:692-702.
17. Lister R,Pelizzola M,Dowen RH, et al.Human DNA methylomes at base resolution show widespread epigenomic differences.Nature. 2009;462:315-22.
18. Li Y,Zhu J,Tian G, et al.The DNA methylome of human peripheral blood mononuclear cells.PLoS Biol. 2010;8:.
19. Lister R,Pelizzola M,Kida YS, et al.Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells.Nature. 2011;471:68-73.
20. Yan XJ,Xu J,Gu ZH, et al.Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia.Nat Genet. 2011;43:309-15.
21. Simó-Riudalbas L,Melo SA,Esteller M.DNMT3B gene amplification predicts resistance to DNA demethylating drugs.Genes Chromosomes Cancer. 2011;50:527-34.
22. Véron N,Peters AHNature. 2011:293-4.
23. He YF,Li BZ,Li Z, et al.Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA.Science. 2011;:.
24. Fraga MF,Ballestar E,Villar-Garea A, et al.Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.Nat Genet. 2005;37:391-400.
25. Seligson DB,Horvath S,Shi T, et al.Global histone modification patterns predict risk of prostate cancer recurrence.Nature. 2005;435:1262-6.
26. Varambally S,Dhanasekaran SM,Zhou M, et al.The polycomb group protein EZH2 is involved in progression of prostate cancer.Nature. 2002;419:624-9.
27. Cloos PA,Christensen J,Agger K, et al.The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.Nature. 2006;442:307-11.
28. Ropero S,Fraga MF,Ballestar E, et al.A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.; 2006; 2006. 566.
29. Morin RD,Johnson NA,Severson TM, et al.Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.Nat Genet. 2010;42:181-5.
30. van Haaften G,Dalgliesh GL,Davies H, et al.Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.Nat Genet. 2009;41:521-3.
31. Jones S,Wang TL,Shih IeM, et al.Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.Science. 2010;330:228-31.
32. Varela I,Tarpey P,Raine K, et al.Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.Nature. 2011;469:539-42.
33. Tan J,Yang X,Zhuang L, et al.Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.Genes Dev. 2007;21:1050-63.
34. Daigle SR,Olhava EJ,Therkelsen CA, et al.Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.Cancer Cell. 2011;20:53-65.
35. Lara E,Mai A,Calvanese V, et al.Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.Oncogene. 2009;28:781-91.
36. Huertas D,Soler M,Moreto J, et al.Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin.Oncogene. 2011;:.
37. Melo S,Villanueva A,Moutinho C, et al.Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing.Proc Natl Acad Sci USA. 2011;108:4394-9.